Under the agreement, Centogene will continue providing Takeda access to diagnostic testing for patients around the world. The commercial fee-for-service agreement focuses on expanding patient access to diagnostics for lysosomal storage disorders such as Fabry and Gaucher diseases, and Hunter syndrome.
Kim Stratton, CEO of Centogene said: “We are excited to extend our partnership with Takeda to provide diagnostics and accelerate improved treatment and health outcomes for patients globally,”. She also stated: “With our highly differentiated diagnostic services, Centogene’s network of over 29,000 physicians, and the Centogene Biodatabank driving novel insights, we are uniquely positioned to add significant value to biopharma partners along their entire development pipeline. This collaboration will support the expansion of Takeda’s world-class enzyme replacement treatments and most importantly, bring real solutions to under-served patient communities.”
Within the partnership, Centogene’s proprietary CentoCard® dried blood spot solution provides easy logistics for central diagnostic testing. A key asset to the partnership is the Centogene Biodatabank, the world’s largest real-world data repository for rare and neurodegenerative diseases, which is pioneering access to commercial multiomic products on the market today.
In January 2015, Centogene originally entered into an agreement with Shire Pharmaceuticals, which was acquired in 2019 by Takeda, to provide diagnostic testing capability to enhance early diagnosis of patients suffering from genetic rare diseases. Last year, the contract was extended until March 2022.
The link to the article can be found here.